
Sign up to save your podcasts
Or


The approved COVID-19 vaccines developed by Moderna and the Pfizer and BioNTech partnership use genetic material called messenger RNA to effectively transform the body’s own cells into vaccine factories. This approach is a first for vaccines. It relies on decades of clinical research into whether messenger RNA technology can be used to treat a broad range of ailments, from cancer to the seasonal flu. Naomi Kresge explores whether the validation of this breakthrough technology during COVID-19 could bring about a whole new field of medicine.
See omnystudio.com/listener for privacy information.
By Bloomberg3.7
805805 ratings
The approved COVID-19 vaccines developed by Moderna and the Pfizer and BioNTech partnership use genetic material called messenger RNA to effectively transform the body’s own cells into vaccine factories. This approach is a first for vaccines. It relies on decades of clinical research into whether messenger RNA technology can be used to treat a broad range of ailments, from cancer to the seasonal flu. Naomi Kresge explores whether the validation of this breakthrough technology during COVID-19 could bring about a whole new field of medicine.
See omnystudio.com/listener for privacy information.

78,678 Listeners

32,092 Listeners

6,763 Listeners

28,944 Listeners

16,195 Listeners

2,682 Listeners

405 Listeners

2,189 Listeners

1,982 Listeners

420 Listeners

12,227 Listeners

17,603 Listeners

969 Listeners

112,220 Listeners

197 Listeners

30 Listeners

10,183 Listeners

5 Listeners

58 Listeners

233 Listeners

232 Listeners

65 Listeners

75 Listeners

86 Listeners

403 Listeners

18 Listeners

12 Listeners

7 Listeners

2 Listeners

114 Listeners

1,146 Listeners

184 Listeners